Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
FORTE Trial Set to Examine Optimal Colonoscopy Frequency for CRC Prevention
October 27th 2021The randomized FORTE/NRG-CC005 trial, which is evaluating the frequency of surveillance colonoscopy in individuals with a first-time presentation and removal of 1 to 2 small, benign polyps, has been launched.
Read More
Scope of Treatment Sequencing Grows in Genitourinary Malignancies
October 26th 2021Jonathan A. Chatzkel, MD, discusses updates in first-line treatment options for metastatic urothelial cancer, as well as recommended treatments for patients with previously treated, locally advanced or metastatic urothelial cancer, and also newly diagnosed metastatic renal cell carcinoma.
Read More
Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL
October 21st 2021The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.
Read More
Nurse Practitioners Are a Touchstone in Lung Cancer Management
October 14th 2021Communication and education of a patient with lung cancer and their family is only part of a nurse practitioner’s responsibility. Moreover, they often represent the primary point of contact for a patient when it comes to their diagnostic workup, treatment follow-up, and symptom management.
Read More
PROMIS Scores Provide Insight Into PROs With Radiation Therapy in Soft Tissue Sarcoma
October 14th 2021Patient Reported Outcomes Measurement Information System scoring indicated that preoperative and postoperative radiation therapy was associated with worse anxiety and physical function in patients with soft tissue sarcoma who had resulting wound complications compared with those who did not.
Read More
Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC
October 12th 2021The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.
Read More
Sarah Cannon Research Institute Experts Pinpoint Open Clinical Trials in Tennessee
October 11th 2021Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.
Read More
Maintenance Therapy, Adjuvant and Escalated Approaches Garner Excitement in GU Cancers
October 11th 2021Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.
Read More
SERDs, ADCs Broaden Research Avenues Throughout Breast Cancer
October 8th 2021Selective estrogen receptor degraders and antibody-drug conjugates are not only broadening the armamentarium in breast cancer but are demonstrating increasing utility across subtypes and in underserved populations, such as those with HER2-low disease, explained Erika P. Hamilton, MD.
Read More
Immunotherapy, Second-Generation AR Antagonists Provide Expansive Utility Throughout Prostate Cancer
October 7th 2021Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.
Read More
MSH3 IHC and Tetranucleotide MSI Analysis Should Not Be Routine in CRC
October 7th 2021MSH3 immunohistochemistry and tetranucleotide analysis failed to demonstrate concordance in identifying microsatellite instability in a cohort of colorectal cancer cases at selected tetranucleotide repeats, suggesting that the dual assessment strategy is not ready for routine use in diagnostic workup.
Read More
Key Advances Showcase the Potential of Precision Medicine in NSCLC
October 5th 2021The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.
Read More
Treatment Should Not Be Dependent on Age in Soft Tissue Sarcoma
October 4th 2021Soft tissue sarcoma was the primary cause of death in patients over the age of 75 years, indicating that age alone should not be a prohibitive factor for treatment in older patients, according to findings from a retrospective analysis that was presented at the 2021 ESMO Congress.
Read More
Concurrent Immunotherapy and Chemoradiation Under Study in Stage III NSCLC
October 4th 2021Martin F. Dietrich, MD, PhD, discusses the significance of the PACIFIC trial on clinical practice and research efforts in stage III non–small cell lung cancer, expectations for ongoing clinical trials, and the emergence of targeted therapy in the adjuvant setting
Read More
Rovalpituzumab Tesirine Falls Flat in Small Cell Lung Cancer
October 1st 2021Rovalpituzumab tesirine failed to show an efficacy or safety benefit as a frontline, maintenance, and second-line treatment for patients with advanced small cell lung cancer, warranting its discontinued development.
Read More
Cabozantinib Maintains PFS Advantage in Pretreated Differentiated Thyroid Cancer
September 29th 2021Cabozantinib demonstrated a sustained benefit in progression-free survival vs placebo in patients with previously treated, radioactive iodine–refractory differentiated thyroid cancer, regardless of prior exposure to sorafenib or lenvatinib.
Read More
Clinical Trials Prevail Despite the Continued COVID-19 Pandemic
September 27th 2021Clinical trial enrollments underwent a substantial decrease during the first year of the COVID-19 pandemic only to rebound during the winter 2020 to 2021 wave, and primarily affected enrollment to cancer control and prevention trials vs treatment trials.
Read More
Targeted Therapy Drives Improves Outcomes Throughout Lung Cancer Subtypes
September 24th 2021The availability of targeted agents for patients with advanced non–small cell lung cancer who harbor mutations in EGFR, RET, MET, and KRAS has not only led to improved outcomes, but provided greater flexibility for treatment-naïve and pretreated populations, with the possibility of enhanced intracranial activity.
Read More
High HER2 Expression Is Linked With Improved Outcomes With Trastuzumab Deruxtecan in HER2+ mCRC
September 21st 2021Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.
Read More